| NCT ID | NCT03568994 |
| Title | Atovaquone (Mepron) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Baylor College of Medicine |
| Indications | |
| Therapies |
Atovaquone + Cytarabine + Daunorubicin + Etoposide Atovaquone + Cytarabine + Daunorubicin + Gemtuzumab ozogamicin |
| Age Groups: | adult child |